Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices.

The aim of this study was to compare the efficacy and safety of cap-assisted endoscopic injection sclerotherapy (EIS) versus direct EIS in the management of esophageal variceal bleeding in patients with cirrhosis. This retrospective study included patients with cirrhosis and esophageal variceal bleeding who underwent EIS with or without the use of a transparent cap at Shandong Provincial Hospital between December 2014 and April 2017. Patients were divided into two groups: Group A (EIS with transparent cap, n=50) and Group B (direct EIS, n=45). Data collected included patients' demographics, procedure details, and rates of variceal eradication, variceal rebleeding, variceal recurrence, and survival during the follow-up period. All data were expressed as mean +/- SD. Quantitative variables were compared with Student t test; qualitative variables were compared with the Fisher exact test or chi-square test. P values less than .05 were considered significant. The mean follow-up duration was similar in both groups (16.3 +/- 10.2 mo in Group A and 15.5 +/- 9.5 mo in Group B). The volume of sclerosant (64.86 +/- 10.62 vs 104.73 +/- 21.25 ml, P=.044), mean number of sessions (2.37 +/- 1.15 vs 5.70 +/- 1.57, P=.042), time required to perform endoscopic treatment (6.57 +/- 1.50 vs 11.22 +/- 2.29 minutes, P=.049), and time to initial esophageal varices eradication (5.43 +/- 1.38 vs 8.93 +/- 1.5 wk, P=.041) were significantly smaller in the cap-assisted EIS group than in the direct EIS group. The probability of variceal recurrence and rebleeding was significantly higher in the direct EIS group than in the cap-assisted EIS group (14% versus 35.6% and 20% versus 40%). Only 22 patients (44%) developed complications in the cap-assisted group versus 30 patients (66.7%) in the EIS group (P=.039). The probability of survival was similar in both groups (86% versus 75.6%, P=.133). Modified EIS with the use of a transparent cap resulted in lower rates of esophageal variceal recurrence, rebleeding, and complications, compared with direct EIS.